- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Poseida Therapeutics Inc (PSTX)Poseida Therapeutics Inc stock price live, this page displays NASDAQ PSTX stock exchange data. View the PSTX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Poseida Therapeutics Inc real time stock price chart below.
What Is the Poseida Therapeutics Inc Stock Price Today?
The Poseida Therapeutics Inc stock price today is 9.450.
What Is the Stock Symbol for Poseida Therapeutics Inc?
The stock ticker symbol for Poseida Therapeutics Inc is PSTX.
Is PSTX the Same as $PSTX?
$PSTX is a common way to refer to the Poseida Therapeutics Inc ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Poseida Therapeutics Inc Trade On?
Poseida Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Poseida Therapeutics Inc a Good Stock to Buy?
Determining whether Poseida Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Poseida Therapeutics Inc share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PSTX quote. (ISIN: US73730P1084)
What Is the Poseida Therapeutics Inc Stock Price Today?
The Poseida Therapeutics Inc stock price today is 9.450.
What Is the Stock Symbol for Poseida Therapeutics Inc?
The stock ticker symbol for Poseida Therapeutics Inc is PSTX.
Is PSTX the Same as $PSTX?
$PSTX is a common way to refer to the Poseida Therapeutics Inc ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Poseida Therapeutics Inc Trade On?
Poseida Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Poseida Therapeutics Inc a Good Stock to Buy?
Determining whether Poseida Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Poseida Therapeutics Inc share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PSTX quote. (ISIN: US73730P1084)
9.450
+0.010(+0.11%)
Closed
After Hours
9.430-0.020(-0.212%)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
9.400
9.500
52 wk Range
1.870
9.500
PSTX Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Trading near 52-week High
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
9.4009.500
52 wk Range
1.8709.500
Key Statistics
Edit
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
PSTX Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceFair Price
Upside
Technical Analysis
Strong Buy
Analysts Sentiment
Neutral
Price Target
9.500
Upside
+0.529%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales growth in the current year
- Roche commences tender offer for all shares of Poseida Therapeutics
- Investing.com
Pro
- Roche commences tender offer for all shares of Poseida Therapeutics
- Investing.com
Pro
Poseida Therapeutics Inc Company Profile
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company’s development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications. It is also involved in the development of P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, colorectal, lung, ovarian, pancreatic, and renal cancers; P-PSMA-ALLO1, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in preclinical development for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC); and P-PSMA-101, an allogeneic CAR-T product candidate under Phase 1 clinical trial for treating mCRPC. In addition, the company engages in the development of P-FVIII-101, a clinical stage liver-directed gene therapy for the in vivo treatment of hemophilia A; P-OTC-101, a clinical stage liver-directed gene therapy for the in vivo treatment of ornithine transcarbamylase deficiency; and P-PAH-101, a clinical stage liver-directed gene therapy for the in vivo treatment of phenylketonuria. It has a research collaboration and license agreement with F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. The company was incorporated in 2014 and is headquartered in San Diego, California.
Poseida Therapeutics Inc SWOT Analysis
Market Potential | Analysts set price targets ranging from $10 to $20, reflecting optimism about Poseida's innovative approach in the expanding gene and cell therapy markets |
Clinical Milestones | Explore Poseida's promising early-stage data, including a 60% objective response rate in multiple myeloma and advancements in non-viral gene therapies |
Financial Fortitude | With a pro forma cash position of $264 million, Poseida is well-funded to advance its diverse pipeline into the second half of 2025 |
Gene Therapy Pionee | Poseida Therapeutics leverages proprietary gene editing and cell therapy technologies, positioning itself as a key player in novel therapeutics development |
Compare PSTX to Peers and Sector
Metrics to compare | PSTX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPSTXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −15.1x | −1.4x | −0.7x | |
PEG Ratio | −0.26 | −0.01 | 0.00 | |
Price / Book | 10.6x | 1.9x | 2.6x | |
Price / LTM Sales | 6.1x | 9.2x | 3.2x | |
Upside (Analyst Target) | 0.6% | 309.3% | 47.1% | |
Fair Value Upside | Unlock | 40.0% | 7.3% | Unlock |
Analysts' Recommendations
0 Buy
5 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Neutral
Analysts 12-Month Price Target:
Average 9.500
(+0.53% Upside)
People Also Watch
FAQ
What Is the Poseida (PSTX) Stock Price Today?
The Poseida stock price today is 9.45
What Stock Exchange Does Poseida Trade On?
Poseida is listed and trades on the NASDAQ stock exchange.
What Is the Stock Symbol for Poseida?
The stock symbol for Poseida is "PSTX."
What Is the Poseida Market Cap?
As of today, Poseida market cap is 921.55M.
What is Poseida Earnings Per Share?
The Poseida EPS is -0.63.
What Is the Next Poseida Earnings Date?
Poseida will release its next earnings report on Mar 06, 2025.
From a Technical Analysis Perspective, Is PSTX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.